Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre Boonstra

International Workshop on HBV Cure 2018

Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MD

International Workshop on HBV Cure 2018

Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhD

International Workshop on HBV Cure 2018

What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH

International Workshop on HBV Cure 2018

Antiviral effect of the RIG-I agonist, Inarigavir | Nezam Afdahl

International Workshop on HBV Cure 2018

Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhD

International Workshop on HBV Cure 2018

Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong Zhu

International Workshop on HBV Cure 2018

Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela Paulsen

International Workshop on HBV Cure 2018

Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele Armenia

European HIV Clinical Forum 2018

Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSC

European HIV Clinical Forum 2018

Long-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCP

European HIV Clinical Forum 2018

Pharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmD

European HIV Clinical Forum 2018

Intergrase inhibitors- What's new?-Margaret Johnson, MD

European HIV Clinical Forum 2018

Resistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhD

European HIV Clinical Forum 2018

Reduced drug regimens- What are the data?- Jose Arribas, MD

European HIV Clinical Forum 2018

Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhD

European HIV Clinical Forum 2018

CPK/PD Support for a Phase 1 Study of TBA-7371- Jerry Nedelman, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect- Lénaïg Tanneau, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

TPreclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid- Suresh Mallikaarjun, PHD, FCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline- An Vermeulen, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention- Anthony Podany, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB- Andrew McCallum, MBChB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers- Charles Peloquin, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018

Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis-Sean Wasserman, MBChB, MMed

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018